# 2026-12142: Company Seeks DEA Permit to Import Methamphetamine

2026-12142, Importer of Controlled Substances Application: Aphena Pharma Solutions MD, LLC, is a Federal Register notice from Justice Department, Drug Enforcement Administration published 2026-06-17, effective Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on, or objections to the issuance of the proposed registration on or before July 17, 2026. Such persons may also file a written request for a hearing on the application on or before July 17, 2026. (as of 2026-06-24).

- Canonical: https://policyrisk.com/federal-register/2026-12142
- As of: 2026-06-24
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-12142
- Title: Importer of Controlled Substances Application: Aphena Pharma Solutions MD, LLC
- Type: Notice
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 91 FR 36619
- Published: 2026-06-17
- Effective: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on, or objections to the issuance of the proposed registration on or before July 17, 2026. Such persons may also file a written request for a hearing on the application on or before July 17, 2026.
- Comments close: 2026-07-17
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-24

## In one line

Company Seeks DEA Permit to Import Methamphetamine

## Summary

Aphena Pharma Solutions MD, LLC wants to become an official importer of methamphetamine, a controlled substance. People and companies involved with these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could affect how methamphetamine is imported and tracked, with no immediate cost changes announced.

## Abstract

Aphena Pharma Solutions MD, LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-20749](https://policyrisk.com/federal-register/2026-20749): Vladimir Romaniv, P.A.; Decision and Order, 2026-10-09
- [2026-20750](https://policyrisk.com/federal-register/2026-20750): L Krenk DBA Maui Clinic Pharmacy; Decision and Order, 2026-10-09

## Sources
- [2026-12142 on federalregister.gov](https://www.federalregister.gov/documents/2026/06/17/2026-12142/importer-of-controlled-substances-application-aphena-pharma-solutions-md-llc)
- [2026-12142 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-06-17/pdf/2026-12142.pdf)

## Related
- [Previous: 2026-12141, Importer of Controlled Substances Application: Veranova, L.P.](https://policyrisk.com/federal-register/2026-12141)
- [Next: 2026-12143, Importer of Controlled Substances Application: AndersonBrecon, Inc. DBA PCI Pha…](https://policyrisk.com/federal-register/2026-12143)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-12142 (as of 2026-06-24).